Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146619

Pw146619 View Pathway
drug action

Pramiracetam Drug Metabolism Action Pathway

Homo sapiens

PW145355

Pw145355 View Pathway
drug action

Pramlintide Drug Metabolism Action Pathway

Homo sapiens

PW146104

Pw146104 View Pathway
drug action

Pramocaine Drug Metabolism Action Pathway

Homo sapiens

PW145496

Pw145496 View Pathway
drug action

Prasterone Drug Metabolism Action Pathway

Homo sapiens

PW146964

Pw146964 View Pathway
drug action

Prasterone enantate Drug Metabolism Action Pathway

Homo sapiens

PW122427

Pw122427 View Pathway
drug action

Prasugrel Action

Homo sapiens

PW128062

Pw128062 View Pathway
drug action

Prasugrel Action Pathway

Homo sapiens
Prasugrel is a platelet inhibitor acting to reduce thrombotic events, its brand name is Effient or Efient. It is a prodrug meaning that once administered orally it goes through first-pass metabolism in the liver to be metabolized to its active form. Once in its active form it travels to the bloodstream and acts on the P2Y12 receptor in platelets. By irreversibly binding to the P2Y12 receptors it impairs ADP mediated activation of glycoprotein GPIIb/IIIa complex. Due to the anticoagulant and antiplatelet activity, it is recommended to avoid herbs and supplements with similar activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba.

PW145678

Pw145678 View Pathway
drug action

Prasugrel Drug Metabolism Action Pathway

Homo sapiens

PW176400

Pw176400 View Pathway
metabolic

Prasugrel Predicted Metabolism Pathway

Homo sapiens
Metabolites of Prasugrel are predicted with biotransformer.

PW000133

Pw000133 View Pathway
drug action

Pravastatin Action Pathway

Homo sapiens
Pravastatin inhibits cholesterol synthesis via the mevalonate pathway by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is the enzyme responsible for the conversion of HMG-CoA to mevalonic acid, the rate-limiting step of cholesterol synthesis by this pathway. Pravastatin bears a chemical resemblance to the reduced HMG-CoA reaction intermediate that is formed during catalysis. Structure-activity relationship studies have demonsotrated that statins bind to HMG-CoA reductase at the same site as the reduced reaction intermediate and are held in place by similar chemical interactions. Cholesterol biosynthesis accounts for approximately 80% of cholesterol in the body; thus, inhibiting this process can significantly lower cholesterol levels. Pravstatin was derived from the microbial transformation of mevastatin, which is a natural compound produced by Penicillium citinium and the first statin ever studied. Unlike lovastatin and simvastatin, pravastatin is relatively hydrophilic and does not require hydrolysis for activation. Increased hydrophilicity accounts for its decreased penetration of lipophilic peripheral cells, increased selectivity for hepatic tissues and decreased side effects relative to simvastatin and lovastatin.